Modality
Gene Therapy
MOA
VEGFi
Target
WRN
Pathway
Apoptosis
Ovarian CaMigraineWet AMD
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
~Sep 2018
→ ~Dec 2019
Phase 2
~Mar 2020
→ ~Jun 2021
Phase 3
~Sep 2021
→ ~Dec 2022
NDA/BLA
Mar 2023
→ Sep 2027
NDA/BLACurrent
NCT03539333
457 pts·Wet AMD
2023-03→2027-09·Active
457 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-261.5y awayPh3 Readout· Wet AMD
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2027-09-26 · 1.5y away
Wet AMD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03539333 | NDA/BLA | Wet AMD | Active | 457 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa |